Lora Weiselberg

3.1k citations
33 papers · 2.5k · 3 hit papers · h-index 16

Impact in

  • Surgery top 2%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies
  • Genetics top 5%
    • Chronic Lymphocytic Leukemia Research

Papers in

Lora Weiselberg

33 papers receiving 2.4k citations

Lora Weiselberg's Hit Papers

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse 1989 · 540 citations
5400+13+27Years since publication100200300400500

Peers

Lora Weiselberg
Comparison fields: 5 of 91
  • Surgery 1.3k
  • Genetics 292
  • Oncology 575
  • Urology 129
  • Pulmonary and Respiratory Medicine 556
Replace Adam Pawinski with:
Adam Pawinski Norway
Ryoichi Nakanishi Japan
Dennis R. Holmes United States
Jun Miki Japan
Hirohito Kobayashi Japan
H.F.P. Hillen Netherlands
F Baillet France
Eble Jn United States
A P Sappino Switzerland
Piotr Czauderna Poland
Lora Weiselberg relative to Adam Pawinski Norway Adam Pawinski's profile →
Citations per field
00.5×8.1×
Adam Pawinski · 1×
Citations per year

Countries citing papers authored by Lora Weiselberg

Since Specialization
Citations

This map shows the geographic impact of Lora Weiselberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lora Weiselberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lora Weiselberg more than expected).

Fields of papers citing papers by Lora Weiselberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lora Weiselberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lora Weiselberg. The network helps show where Lora Weiselberg may publish in the future.

Co-authors

The 25 scholars most cited alongside Lora Weiselberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lora Weiselberg Line = papers co-authored together Lora Weiselberg links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
Hit paper breakdown →
1989540
2
Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
Hit paper breakdown →
1985513
3
M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium
Hit paper breakdown →
1988494
4 2017284
5 1989247
6 202149
7 199943
8
Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
198834
9 199234
10 202126
11
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
199120
12
Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma.
198319
13 198418
14
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
198517
15 199116
16
Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
198215
17 198313
18 199911
19
Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
198511
20
Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
19817

About Lora Weiselberg

Lora Weiselberg is a scholar working on Oncology, Molecular Biology, Genetics, Surgery and Pulmonary and Respiratory Medicine, having authored 33 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Bladder and Urothelial Cancer Treatments (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Urinary and Genital Oncology Studies (3 papers), Cancer-related cognitive impairment studies (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Breast Cancer Treatment Studies (2 papers) and Chemotherapy-induced organ toxicity mitigation (2 papers). The work is most often cited by research in Surgery (1.3k citations), Genetics (292 citations), Oncology (575 citations), Urology (129 citations) and Pulmonary and Respiratory Medicine (556 citations). Lora Weiselberg has collaborated with scholars based in United States. Frequent co-authors include Pramod C. Sogani, Nancy L. Geller, Howard I. Scher, Willet F. Whitmore, Alan Yagoda, Harry W. Herr, Michael J. Morse, Robin C. Watson, Cora N. Sternberg and Phyllis Hollander. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, Cancer, Age and Ageing and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact